Fall in third quarter vaccine salesFull year profit reiteratedQ3 dividend of 15p per shareDisappointing vaccine sales took the shine off GSK's (GSK) third quarter update and despite management reiterating full-year sales and profit guidance, the shares sank to the bottom of the FTSE, falling 3.6% to £13.99.The shares languish near one-year lows and sit just 14% above the five-year low, which mean

European stocks were higher on Thursday midday, as investors prepare for a US GDP print, while top US White House aide Jake Sullivan met Chinese President Xi Jinping in Beijing.The FTSE 100 index was up 24.13 points, or 0.3%, at 8,367.98. The FTSE 250 was up 42.84 points, or 0.2%, at 21,109.71, and the AIM All-Share was up 2.36 points, or 0.3%, at 772.66.The Cboe UK 100 was up 0.3% at 836.44, the

Stock prices in London opened softly in the green on Thursday as investors remained cautious ahead of upcoming US GDP data.The FTSE 100 index opened up just 4.00 points at 8,347.85. The FTSE 250 was down 11.24 points, or 0.1%, at 21,055.63, and the AIM All-Share was up 1.74 points, or 0.2%, at 772.04.The Cboe UK 100 was up slightly at 834.44, the Cboe UK 250 was down a little at 18,563.12, and the

At the end of last year the market was pricing in 1.7% worth of US rate cuts for 2024 but here we are in late August and the Federal Reserve is yet to pull the trigger, largely due to stickier-than-expected inflation.However, after a series of false dawns, we may finally be approaching the point where the Fed acts, with a rate cut widely expected on 18 September. The debate largely centres on whet

Q2 sales and earnings beat estimatesShares plunge on full-year downgradeRSV vaccine doses ship ahead of winterInvestors can be a tough bunch to please, just beating expectations is often not enough.Biotechnology firm Moderna (MRNA) is a case in point, with its shares slumping 21% overnight despite second quarter earnings coming in ahead of Wall Street estimates as the company slashed its full year

US Centre for Disease Control restricts vaccine useDecision could limit vaccine salesGSK has a leading market share in RSV vaccinesShares in GSK (GSK) were marked down 5% to £15.16 after the US CDC (Centre for Disease Control) advised a narrower use of RSV (respiratory syncytial virus) vaccines, cutting the potential market for GSK's leading Arexvy vaccine.The drop eradicates most the year's gain

Equities in London made a slow start on Thursday, but peers in Europe traded more confidently, with market focus on upcoming US data and political developments either side of the English Channel, and across the Atlantic.In London, a US blow for GSK hurt its shares. Miners also struggled in early dealings. Elsewhere, there was a guidance boost for outsourcer Serco, Watches of Switzerland reported i

Covid-19 stock market darling Moderna (MRNA) appears to be getting its mojo back with investors following a punishing 85% drop in the shares from their September 2021 highs.Over the last six months Moderna's shares have more than doubled and despite the fall over the past couple of years, they remain one of the best performers in the benchmark S&P 500, notching up gains of 880% over the last five

Positive readout for combined vaccineFirst-ever positive results from late-stage trialModerna is developing non-Covid vaccinesUS biotechnology firm Moderna (MRNA:NASDAQ), best known for its Covid-19 vaccine based on its unique mRNA technology, said its combined flu and Covid-19 drug provoked a higher immune response than separate single jabs in late-stage clinical trials.The shares gained 2% in pr

Better than expected Q1 sales and narrower lossCovid vaccine sales plunged 90% year on yearRSV vaccine expected to be approvedUS biotechnology firm Moderna (MRNA:NASDAQ) surged 13% after reporting a smaller than expected quarterly loss and reaffirming the timeline for expected regulatory approval of its RSV (respiratory syncytial virus) vaccine.Management said it expects the regulator to announce

Cancer drug gets positive readoutPotential for personalised medicinesModerna has over 45 drugs in developmentUS biotechnology firm Moderna (MRNA:NASDAQ) was the top performer in the S&P 500 on Tuesday (9 April) jumping as much as 10% after its personalised cancer vaccine showed positive results in an early stage trial.The shares closed 6% higher at $11.60, a new three month high, but are down 30%

Equities in London went into Wednesday afternoon in largely negative territory, though peers in Europe were in the green and equities in New York are called higher.Nonetheless, there was still some trepidation in the air ahead of a US inflation reading on Friday.Some of the FTSE 100?s heavyweights weighed on the index. Shell and BP fell 1.3% and 1.5% as Brent prices fell. HSBC lost 1.7% after Barc

London?s FTSE 100 edged lower after the opening bell on Wednesday, as investors moved with trepidation as eyes turn to a US inflation reading due later in the week.The FTSE 100 index opened down 13.02 points, 0.2%, at 7,917.94. The FTSE 250 was down 23.35 points, 0.1%, at 19,754.29, and the AIM All-Share was up 0.27 of a point at 739.79.The Cboe UK 100 was down 0.2% at 791.57, the Cboe UK 250 was

Stock markets have been making new all-time highs in the US, Europe and Japan and investors are asking whether they are witnessing a new global bull market for stocks which began in November 2023.Momentum is a powerful factor in stock markets. Prices tend to trend in the same direction which mean buying winners and selling losers can be a profitable strategy.It is not only about price but also ear

A lot was riding on Nvidia?s (NVDA:NASDAQ) latest quarterly update with the strong run for the shares leaving little margin for error. However, it delivered and the S&P 500 and Dow Jones Industrial Average reached new record highs. The big loser this week was Palo Alto Networks (PANW:NASDAQ) which endured a major slump in its share price after revealing softer client spending and steep promotions

Stock prices in London inched up on Monday as wider European markets lacked direction while US markets were closed for George Washington?s birthday.The FTSE 100 index closed up 16.79 points, 0.2%, at 7,728.50. The FTSE 250 ended up 24.97 points, 0.1%, at 19,216.90, and the AIM All-Share closed up 2.45 points, 0.3%, at 756.33.The Cboe UK 100 ended up 0.3% at 773.62, the Cboe UK 250 closed up 0.2% a

Stock prices in London had little direction on Wednesday morning, ahead of crucial interest rate decisions by the US Federal Reserve and the Bank of England.The FTSE 100 index opened up 2.76 points at 7,669.07. The FTSE 250 was down 11.48 points at 19,338.02, and the AIM All-Share was down 0.19 of a points at 754.70.The Cboe UK 100 was down 0.1% at 765.96, the Cboe UK 250 was down 0.1% at 16,798.2

In a slightly choppy week for Wall Street, as December?s inflation reading came in ahead of expectations at 3.4%, US stocks were ultimately dragged higher by the big tech firms which powered the markets in 2023.Positive comments from Nvidia (NVDA:NASDAQ) chief financial officer Collette Kress and news of three new graphics chips helped propel the company to double-digit gains for the week.Cyber se

London?s FTSE 100 made a tepid start to 2024, with underwhelming manufacturing data from the UK and eurozone doing little to lift sentiment.Equities in New York are called to open lower ahead of a key week for the US interest rate outlook. The latest Federal Reserve meeting minutes are released on Wednesday, before the official US jobs report on Friday.The FTSE 100 index was down 29.34 points, 0.4

Stocks in London mostly advanced on Tuesday as the New Year got underway, with investors digesting the latest manufacturing PMIs from major economies.The FTSE 100 index opened up 21.88, 0.3%, at 7,755.12. The FTSE 250 was down 12.20 points, 0.1%, at 19,677.43, and the AIM All-Share was 1.76 points, 0.2%, at 765.08.The Cboe UK 100 was up 0.2% at 774.07, the Cboe UK 250 was up 0.1% at 17,184.40, and